10-Q quarterly report · filed Nov 5, 2026

CASTLE BIOSCIENCES INC (CSTL) Q3 2026 10-Q Quarterly Report

Short answer

CASTLE BIOSCIENCES INC (CSTL) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $103M (up 23.9% year over year) with net income of −$4M.

Q3 2026 key financials · XBRL

Revenue
$103M
+23.9% YoY · −0.6% QoQ
Net income
−$4M
−718.4% YoY · −99.0% QoQ
Operating margin
-2.7%
EPS (diluted)
−$0.14
−600.0% YoY · −133.3% QoQ

Source: XBRL data from the CASTLE BIOSCIENCES INC (CSTL) Q3 2026 10-Q on SEC EDGAR. USD.

CASTLE BIOSCIENCES INC Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Q3 revenue $102.9M, up 23.9% YoY from $83.0M
  • Gross margin 74.7% vs 74.7% YoY; operating loss $2.7M vs $6.8M
  • Best segment: non-dermatologic revenue $55.0M, up $20.5M; TissueCypher volume up 47%
  • Worst segment: dermatologic revenue $47.9M, down $0.6M; DecisionDx-SCC affected by lost Medicare coverage
  • Cash $78.0M vs $116.7M at year-end; nine-month operating cash flow $12.8M, capital expenditures $28.6M

Risk Factors

  • No material changes overall from the 2025 10-K, aside from updates described below
  • Accumulated deficit $245.0 million at September 30, 2026, versus $224.3 million at December 31, 2025
  • Medicare reimbursement discontinuation for DecisionDx-SCC continued reducing its revenue contribution in 2026
  • New geopolitical risk: February 2026 U.S.-Iran conflict and Strait of Hormuz disruption threaten energy supplies and shipping routes
  • Macroeconomic risk: inflation increased personnel and laboratory supply costs, potentially limiting liquidity and capital access

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other CASTLE BIOSCIENCES INC quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.